Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20870956 | 0.78 | GAA (0.47) | BRD4MAPK14LMNAKCNA3BRD2 | |
| SCHEMBL3225311 | 0.75 | MAPK14 (0.41) | BRD4MAPK14GRM4CYP1A2HDAC4 | |
| SCHEMBL28608527 | 0.73 | TGFBR1 (0.33) | LMNA | |
| SCHEMBL28581896 | 0.72 | PRMT5 (0.38) | BRD4GRM4CYP1A2ALDH1A1LMNA | |
| SCHEMBL10324399 | 0.72 | MAPT (0.47) | CYP1A2ALDH1A1LMNACYP3A4 | |
| SCHEMBL28596660 | 0.71 | GRM4 (0.36) | GRM4CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL714841 | 0.71 | GRM4 (0.34) | GRM4ALDH1A1 | |
| SCHEMBL28917502 | 0.71 | MAPT (0.38) | GRM4USP2ALDH1A1LMNACLK4 | |
| SCHEMBL1371507 | 0.70 | HPRT1 (0.31) | — | |
| SCHEMBL28596710 | 0.70 | CYP2A6 (0.38) | GRM4USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8771843-B2 | Fluorene derivative, organic compound, and light-emitting element, light-emitting device, and electronic device using the compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20120049768-A1 | Fluorene Derivative, Organic Compound, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using the Compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120049768-A1 | Fluorene Derivative, Organic Compound, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using the Compound | AFF2, MAPRE2, AFF4 | BRD4 204/4885MAPK14 2170/4885GRM4 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.